The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I dose escalation study of pan-histone deacetylase (HDAC) inhibitor abexinostat in combination with cisplatin in patients with advanced non-keratinizing nasopharyngeal carcinoma.
Boon C. Goh
No relevant relationships to disclose
Ruey-Long Hong
No relevant relationships to disclose
Wan-Teck Lim
No relevant relationships to disclose
Frédérique Cantero
Employment or Leadership Position - Institut de Recherches Internationales Servier (I. R. I. S.)
Chee-Seng Tan
No relevant relationships to disclose
Renata Robert
Employment or Leadership Position - Institut de Recherches Internationales Servier (I. R. I. S.)